media – Page 7 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

CPhI India

Organiser: Informa Markets Time: November 25-27, 2025 Address: Plot No. 25, 27, 28, 29, Knowledge Park II, Greater Noida, Uttar Pradesh 201306, India Exhibition hall: Greater Noida Product range: APIs: Vitamins, Hormones, Sulfonamides, Analgesics & Antipyretics, Tetracyclines, Amino Acids & Derivatives, Chloramphenicols, Digestive System Drugs, Anti-Infectives, Penicillins, Aminoglycosides, Lincomycins, Cardiovascular Drugs, Antiparasitics, Cephalosporins, Macrolides, Respiratory Drugs, Central Nervous System Drugs, Other Western APIs. Packaging & Equipment: Pharmaceutical Machinery, Packaging Machinery, Packaging Materials, Drug Production Equipment & Technology, Pharmaceutical Packaging Systems, Cleaning/Sterilization Systems, Laboratory Instrumentation. Pharmaceutical Products: Traditional Chinese Medicines, Western Drugs, New Drugs, Chemical Pharmaceuticals, Intermediates, Biopharmaceuticals, Herbal Medicines, Plant/Animal Extracts, Veterinary Drugs, Food Ingredients & Additives. About CPhI India： The CPhI India World Pharmaceutical Ingredient Exhibition is South Asia’s most influential trade fair for pharmaceutical ingredients and machinery. Serving as a premier platform for industry innovation, it connects businesses with India’s leading stakeholders in pharmaceutical machinery, technology, and raw materials. Attendees gain insights ...
- Source: drugdu
- 57
- March 27, 2025
The Yunding Xinyao therapeutic cancer vaccine has been approved for clinical use; Shenji Changhua’s drug for treating ALS has been approved for clinical use

NO.1 Yunding Xinyao Cancer Vaccine Approved for Clinical Use in the United States Yunding Xinyao announced that its universal tumor therapeutic vaccine EVM14 injection has received FDA approval for its IND (New Drug Clinical Trial Application). According to the press release, EVM14 is the company’s first independently developed new drug to receive FDA IND approval. EVM14 is a universal tumor therapeutic vaccine targeting multiple tumor associated antigens (TAA), intended for the treatment of various cancers such as non-small cell lung cancer and head and neck cancer. Comment: Therapeutic vaccines differ from traditional preventive vaccines in that they aim to activate the patient’s immune system to combat pre-existing diseases. EVM14 has been approved for clinical use, opening up new ideas for cancer treatment. It can make up for the limitations of traditional treatment, stimulate patients’ own immunity to fight against tumors, induce immune memory to reduce the risk of recurrence ...
- Source: drugdu
- 49
- March 26, 2025
4 deaths and 17 injuries! Medtronic star products are subject to a first level recall

Recently, the FDA announced a first level recall of Medtronic’s flagship product, the Pipeline Vantage series embolization device. It is reported that the US FDA has listed the recall of the Medtronic (NYSE: MDT) Pipeline Vantage embolization device as the highest level of alert, as the product has initiated an emergency recall procedure due to multiple fatal cases. This recall includes two key measures: complete discontinuation and removal of Pipeline Vantage 027 embolization device; Update the usage guide for Pipeline Vantage 021 device. This series of neurointerventional devices using shielding technology are mainly used for treating intracranial aneurysm like lesions (aneurysms). Its working principle is to deliver the braided stent to the lesion site through a microcatheter, and block the blood flow of the aneurysm using a mesh structure. According to the FDA announcement, this recall is due to adverse stent adherence events that occur frequently in clinical use. Specifically, ...
- Source: drugdu
- 52
- March 26, 2025
WuXi AppTec responds that no AI is needed to develop new drugs! A large number of CXOs are eager to embrace the wave of the times

Affected by this news, both A-shares and H-shares of WuXi AppTec rose on the same day, with A-shares hitting the daily limit up at one point. As of the close, WuXi AppTec’s A-share market price was 69.68 yuan/share, up 8.82%, with a market value of 2021 billion yuan; The Hong Kong stock market quoted 71.95 yuan per share, up 9.93%, with a market value of 207.8 billion yuan. Not only WuXi AppTec, but also companies such as Kanglong Huacheng, Chengdu Pioneer, and Hongbo Pharmaceutical actively embrace AI technology. These CXO giants have coincidentally ventured into the AI field, and what insights do they have for the industry? Medication strategy: HI+AI Thanks to its contract outsourcing model, CXO has significantly reduced research and production costs and improved research and development efficiency for the pharmaceutical industry, making it highly respected in the industry. However, the industry still inevitably faces many uncertain factors ...
- Source: drugdu
- 42
- March 26, 2025
【EXPERT Q&A】What are the implementation standards for DCS systems of pharmaceutical companies?

Drugdu.com expert’s response: DCS (Distributed Control System) is the core automation system in pharmaceutical manufacturing, requiring adherence to three critical objectives: compliance, data integrity, and system reliability. Below is a detailed breakdown based on international regulations, industry practices, and technical requirements: I. International Regulations & Industry Standards GMP Compliance FDA 21 CFR Part 11: Mandates electronic records and signatures, ensuring DCS data storage, modification, and audit trails meet regulatory standards. EU GMP Annex 11: Focuses on computerized system validation, including access control, data backup, and cybersecurity. ICH Q9/Q10: Risk-based quality systems requiring DCS to identify Critical Process Parameters (CPPs) and mitigate quality risks. GAMP 5 Guidelines: Classifies DCS as Category 4 (Configurable Software), requiring full lifecycle validation (URS, FAT, SAT, IQ/OQ/PQ). ISO Standards ISO 9001: Ensures quality management for DCS suppliers. ISO 27001: Protects DCS from cyber threats via information security protocols. II. Technical & Functional Requirements Data Integrity (ALCOA+ Principles) Traceability: Full operational ...
- Source: drugdu
- 63
- March 26, 2025
400 billion yuan, Johnson&Johnson announces big move

Johnson & Johnson to Invest $55 Billion in U.S. Healthcare Infrastructure By Thomas Yuan WILSON, N.C. — In a sweeping move to reinforce America’s life sciences sector, Johnson & Johnson announced on March 21 that it will invest more than $55 billion in its pharmaceutical and medical technology business across the United States over the next four years — a 25 percent increase from its previous investment cycle. The investment, the company said, aims to bolster U.S. manufacturing, research and development, and innovation in fields like oncology, neuroscience, and robotic surgery. It comes as part of a broader effort to maintain America’s global leadership in medical supply and health products, at a time when governments are emphasizing domestic production in response to geopolitical tensions and lessons learned from the pandemic. “We are committed to addressing the world’s toughest healthcare challenges,” said Joaquin Duato, Chairman and CEO of Johnson & Johnson, ...
- Source: drugdu
- 67
- March 25, 2025
The self rescue record of Solventum

Solventum Undertakes $120 Million Overhaul in Strategic Bid for Growth By Thomas Yuan ST. PAUL, Minn. — Solventum, the healthcare spin-off of industrial giant 3M, has entered a new chapter of independence with a bold restructuring effort aimed at reshaping its organizational DNA and strengthening its position in the global medical technology landscape. The company has spent $120 million on its transformation plan — but expects to recoup the entire amount in annual operating cost savings. In a recent investor briefing, Solventum reported that the savings generated in the first year alone will be “sufficient to cover the incremental expenses” of its operations as a newly public company. “This restructuring is not just about cost,” said a company spokesperson in an interview with The Star. “We are optimizing strategic resource allocation to drive long-term business expansion. Our Minnesota-based workforce continues to grow.” From Legacy to Leadership The restructuring, which ...
- Source: drugdu
- 61
- March 25, 2025
AstraZeneca announced a $2.5 billion investment plan to build a new strategic R&D center in Beijing

AstraZeneca to Establish $2.5 Billion R&D Hub in Beijing, Expanding Vaccine and Biotech Partnerships By Thomas Yuan BEIJING — AstraZeneca has unveiled a sweeping $2.5 billion investment plan to build its sixth global strategic research and development center in Beijing, a move that underscores the pharmaceutical giant’s long-term commitment to China’s life sciences sector and its ambitions in biopharmaceutical innovation. The new facility will serve as a cornerstone for AstraZeneca’s expansion in China, with the company also announcing several high-profile partnerships aimed at advancing next-generation drug development and vaccine production. Among the newly signed agreements, AstraZeneca has entered into R&D cooperation with Hebo Pharmaceuticals to pursue multi-specific antibody therapies, as well as a development collaboration with Yuansisheng Peptide focused on macrocyclic peptide drugs, a cutting-edge category of targeted therapies. In addition, the company has launched a joint venture with Kangtai Biological, which will focus on the development, production, and commercialization ...
- Source: drugdu
- 57
- March 25, 2025
Zhifei Biotech invested 593 million yuan to acquire Chen’an Biotech and enter the field of metabolic disease medicine

Zhifei Biotech Acquires Majority Stake in Chen’an Bio to Expand into Therapeutic Biopharmaceuticals By Thomas Yuan CHONGQING — Zhifei Biotech has announced a strategic acquisition to broaden its footprint beyond vaccines and into the realm of therapeutic biopharmaceuticals, investing 593 million yuan (approximately $82 million) to acquire a 51 percent stake in Chen’an Biotech, a Chongqing-based pharmaceutical company focused on metabolic diseases. The deal, finalized on March 21, marks a key milestone in Zhifei’s goal to become a world-class biopharmaceutical company, enabling the firm to diversify its product pipeline and tap into high-growth therapeutic areas like diabetes and obesity. According to an asset appraisal report, the pre-investment valuation of 100 percent of Chen’an Biotech was set at 570 million yuan. Under the agreement, 471 million yuan of Zhifei’s investment will be allocated to Chen’an’s registered capital, while the remaining 122 million yuan will go toward the company’s capital reserves. Upon ...
- Source: drugdu
- 56
- March 25, 2025
Taking the “pass” to the global market and anchoring the 10 billion blue ocean, AIM’s mRNA herpes zoster vaccine has been approved by the United States for clinical trials

AIM Vaccine Gains U.S. FDA Approval for mRNA Shingles Vaccine Trial By Thomas Yuan BEIJING — AIM Vaccine has received approval from the U.S. Food and Drug Administration to begin clinical trials for its mRNA herpes zoster vaccine, the company announced on March 23, marking another major step in its global expansion and bolstering its position as China’s mRNA vaccine pioneer. The new shingles vaccine demonstrated superior performance in preclinical trials, with T cell immunity, IgG antibody titers, and FAMA titers significantly outperforming an internationally available recombinant subunit vaccine, according to third-party testing agencies. The approval is the second green light from the U.S. FDA for AIM’s mRNA pipeline, following the earlier clearance of its mRNA RSV vaccine. With a growing portfolio that includes mRNA candidates for influenza, rabies, and respiratory illnesses, AIM has signaled its intent to compete on the international stage by leveraging its modular mRNA platform — ...
- Source: drugdu
- 54
- March 25, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.